To overcome these barriers, many siRNA delivery systems have been developed. Among these, lipid-based nanoparticles have great potential owing to their biocompatibility and low toxicity in ...

A new study led by Profs. Fan Kelong and Yan Xiyun from the Institute of Biophysics of the Chinese Academy of Sciences ...

which maintains invadopodia—that the company is targeting with lipid nanoparticles carrying chemically modified small interfering RNA (siRNA). Antapodia was founded by Patrick Yang—formerly ...

The global lipid nanoparticles market is expected to grow from USD 271.8 million in 2024 to USD 350.5 million by 2029, with a ...

has demonstrated for the first time that intraperitoneal administration of chitosan nanoparticles containing TNF-specific small interfering RNA (siRNA) could be used to reduce TNF-mediated ...

Creative Biolabs has developed a SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19 treatment. This innovative therapy is based on the short interfering RNA (siRNA) technology that ...

Specifically, I: (i) implemented a lipid-polymer nanoparticle platform for siRNA delivery to bone marrow endothelial cells in vivo to halt myeloma progression, (ii) developed the first-of-its-kind ...

Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president ...

Lipid nanoparticle-based siRNA delivery enables us to fulfill the vision of personalized medicine. *p < 0.05; **p < 0.01. Chol: Cholesterol; FITC: Fluorescein isothiocyanate; FITC–Chol–siRNA ...